A systematic review of loss of independence in Parkinson’s disease

Journal of Neurology

Volumn 263, Issue 1, 2016, Pages 1-10

  Macleod, Angus D ^a   Grieve, J W Kerr ^b   Counsell, Carl E ^a  

^a UNIVERSITY OF ABERDEEN   (United Kingdom)

^b SOUTHERN GENERAL HOSPITAL   (United Kingdom)

Author keywords

Activities of daily living; Dependence; Independence; Parkinson s disease; Systematic review

Indexed keywords

LEVODOPA;

BRADYKINESIA; DEATH; DEPENDENT PERSONALITY DISORDER; DISEASE COURSE; DISEASE DURATION; FOLLOW UP; HUMAN; OBSERVATIONAL STUDY; ONSET AGE; PARKINSON DISEASE; PARKINSONISM; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SYSTEMATIC REVIEW; DAILY LIFE ACTIVITY;

ACTIVITIES OF DAILY LIVING; DISEASE PROGRESSION; HUMANS; PARKINSON DISEASE;

EID: 84955477246     PISSN: 03405354     EISSN: 14321459     Source Type: Journal    
DOI: 10.1007/s00415-015-7847-8     Document Type: Review

References (37)

1. World Health Organization (1980) International classification of impairments, disabilities, and handicaps. World Health Organization, Geneva
2. World Health Organization (2002) Towards a common language for functioning, disability and health. World Health Organization, Geneva
3. Schwab RS, England AC (1969) Projection technique for evaluating surgery in Parkinson’s disease. In: Gillingham FJ, Donaldson MC (eds) Third symposium on Parkinson’s disease. E & S Livingston, Edinburgh, pp 152–157
4. Wade DT, Collin C (1988) The Barthel ADL Index: a standard measure of physical disability? Int Disabil Stud 10(2):64–67
5. Hoehn MM, Yahr MD (1967) Parkinsonism: onset, progression, and mortality. Neurology 17(5):427–442
6. Marras C, Rochon P, Lang AE (2002) Predicting motor decline and disability in Parkinson disease: a systematic review. Arch Neurol 59(11):1724–1728
7. Post B, Merkus MP, de Haan RJ, Speelman JD, Group CS (2007) Prognostic factors for the progression of Parkinson’s disease: a systematic review. Mov Disord 22(13):1839–1851
8. Marinus J, van der Heeden JF, van Hilten JJ (2014) Calculating clinical progression rates in Parkinson’s disease: methods matter. Parkinsonism Relat Disord 20(11):1263–1267. doi:10.1016/j.parkreldis.2014.08.009
9. Berlin JA (1997) Does blinding of readers affect the results of meta-analyses? Lancet 350(9072):185–186. doi:10.1016/s0140-6736(05)62352-5
10. Chia LG, Liu LH (1992) Parkinson’s disease in Taiwan: an analysis of 215 patients. Neuroepidemiology 11(3):113–120
11. Hely MA, Reid WG, Adena MA, Halliday GM, Morris JG (2008) The Sydney multicenter study of Parkinson’s disease: the inevitability of dementia at 20 years. Mov Disord 23(6):837–844
12. Hoehn MM (1985) Result of chronic levodopa therapy and its modification by bromocriptine in Parkinson’s disease. Acta Neurol Scand 71(2):97–106
13. Jasinska-Myga B, Heckman MG, Wider C, Putzke JD, Wszolek ZK, Uitti RJ (2012) Loss of ability to work and ability to live independently in Parkinson’s disease. Parkinsonism Relat Disord 18(2):130–135
14. Sato K, Hatano T, Yamashiro K, Kagohashi M, Nishioka K, Izawa N, Mochizuki H, Hattori N, Mori H, Mizuno Y, Juntendo Parkinson Study G (2006) Prognosis of Parkinson’s disease: time to stage III, IV, V, and to motor fluctuations. Mov Disord 21(9):1384–1395
15. Uitti RJ, Ahlskog JE, Maraganore DM, Muenter MD, Atkinson EJ, Cha RH, Obrien PC (1993) Levodopa therapy and survival in idiopathic Parkinsons-Disease—Olmsted County Project. Neurology 43(10):1918–1926
16. Velseboer DC, Broeders M, Post B, van Geloven N, Speelman JD, Schmand B, de Haan RJ, de Bie RM, Group CS (2013) Prognostic factors of motor impairment, disability, and quality of life in newly diagnosed PD. Neurology 80(7):627–633
17. Scigliano G, Musicco M, Soliveri P, Girotti F, Giovannini P, Fetoni V, Caraceni T (1996) Progression and prognosis in Parkinson’s disease in relation to concomitant cerebral or peripheral vasculopathy. Adv Neurol 69:305–309
18. Aimard G, Henry E, Devic M (1984) Parkinson’s disease. Retrospective study of 302 clinical case records. Presse Med 13(15):919–922
19. Auyeung M, Tsoi TH, Mok V, Cheung CM, Lee CN, Li R, Yeung E (2012) Ten year survival and outcomes in a prospective cohort of new onset Chinese Parkinson’s disease patients. J Neurol Neurosurg Psychiatry 83(6):607–611
20. Guillard A, Chastang C, Fenelon G (1986) Long-term study of 416 cases of Parkinson disease. Prognostic factors and therapeutic implications. Rev Neurol (Paris) 142(3):207–214
21. Yahr MD (1976) Evaluation of long-term therapy in Parkinson’s disease: mortality and therapeutic efficacy. In: Birkmayer W, Hornykiewicz O (eds) Advances in Parkinsonism. Editiones Roche, Basle, pp 435–443
22. Rajput AH, Voll A, Rajput ML, Robinson CA, Rajput A (2009) Course in Parkinson disease subtypes: a 39-year clinicopathologic study. Neurology 73(3):206–212
23. Laupacis A, Wells G, Richardson WS, Tugwell P (1994) Users’ guides to the medical literature. V. How to use an article about prognosis. Evidence-Based Medicine Working Group. JAMA 272(3):234–237
24. Saracci R (2007) Survival-related biases survive well. Int J Epidemiol 36(1):244–246. doi:10.1093/ije/dyl263
25. Rybicki BA, Johnson CC, Gorell JM (1995) Demographic differences in referral rates to neurologists of patients with suspected Parkinson’s disease: implications for case-control study design. Neuroepidemiology 14(2):72–81
26. Evans JR, Mason SL, Williams-Gray CH, Foltynie T, Brayne C, Robbins TW, Barker RA (2011) The natural history of treated Parkinson’s disease in an incident, community based cohort. J Neurol Neurosurg Psychiatry 82(10):1112–1118
27. Alves G, Muller B, Herlofson K, HogenEsch I, Telstad W, Aarsland D, Tysnes OB, Larsen JP (2009) Incidence of Parkinson’s disease in Norway: the Norwegian ParkWest study. J Neurol Neurosurg Psychiatry 80(8):851–857. doi:10.1136/jnnp.2008.168211
28. Caslake R, Taylor K, Scott N, Gordon J, Harris C, Wilde K, Murray A, Counsell C (2013) Age-, gender-, and socioeconomic status-specific incidence of Parkinson’s disease and parkinsonism in northeast Scotland: the PINE study. Parkinsonism Relat Disord 19(5):515–521. doi:10.1016/j.parkreldis.2013.01.014
29. Linder J, Stenlund H, Forsgren L (2010) Incidence of Parkinson’s disease and parkinsonism in northern Sweden: a population-based study. Mov Disord 25(3):341–348. doi:10.1002/mds.22987
30. Herlofson K, Lie SA, Arsland D, Larsen JP (2004) Mortality and Parkinson disease—a community based study. Neurology 62(6):937–942
31. Hemingway H, Croft P, Perel P, Hayden JA, Abrams K, Timmis A, Briggs A, Udumyan R, Moons KGM, Steyerberg EW, Roberts I, Schroter S, Altman DG, Riley RD (2013) Prognosis research strategy (PROGRESS) 1: a framework for researching clinical outcomes. BMJ 346:e5595–e5595. doi:10.1136/bmj.e5595
32. Ramaker C, Marinus J, Stiggelbout AM, Van Hilten BJ (2002) Systematic evaluation of rating scales for impairment and disability in Parkinson’s disease. Mov Disord 17(5):867–876. doi:10.1002/mds.10248
33. Goetz CG, Poewe W, Rascol O, Sampaio C, Stebbins GT, Counsell C, Giladi N, Holloway RG, Moore CG, Wenning GK, Yahr MD, Seidl L (2004) Movement Disorder Society Task Force report on the Hoehn and Yahr staging scale: status and recommendations. Mov Disord 19(9):1020–1028. doi:10.1002/mds.20213
34. Morley D, Selai C, Thompson A (2012) The self-report Barthel Index: preliminary validation in people with Parkinson’s disease. Eur J Neurology 19(6):927–929. doi:10.1111/j.1468-1331.2011.03592.x
35. Riley RD, Hayden JA, Steyerberg EW, Moons KG, Abrams K, Kyzas PA, Malats N, Briggs A, Schroter S, Altman DG, Hemingway H (2013) Prognosis Research Strategy (PROGRESS) 2: prognostic Factor Research. PLoS Med 10(2):e1001380. doi:10.1371/journal.pmed.1001380
36. Macleod AD, Taylor KS, Counsell CE (2014) Mortality in Parkinson’s disease: a systematic review and meta-analysis. Mov Disord 29(13):1615–1622. doi:10.1002/mds.25898
37. McGhee D, Parker A, Fielding S, Zajicek J, Counsell C (2015) Using ‘dead or dependent’ as an outcome measure in clinical trials in Parkinson’s disease. J Neurol Neurosurg Psychiatry 86(2):180–185. doi:10.1136/jnnp-2014-307703